The Amniox Advantage: Addressing the Challenge of Chronic Wounds

The Amniox comprehensive family of umbilical cord and amniotic membrane products harnesses the unique power of human birth tissue to help expedite regenerative healing across a wide range of specialties as the adjunct for acute and chronic wound applications by helping to:

• Facilitate wound healing
• Manage discomfort
• Manage adhesions
• Expedite functional recovery while reducing the cost of care 1-4

BUILT ON A FOUNDATION OF RELENTLESS CLINICAL PURSUIT, DISCOVERY AND COST-EFFECTIVE SOLUTIONS

THE SOLUTION IS IN OUR PLATFORM TECHNOLOGY—HC-HA/PTX3

Our pioneering scientists have focused on understanding the properties of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in healing in the human fetal environment.5-9

This complex may orchestrate anti-inflammatory, anti-scarring and growth-promoting biological effects that may expedite functional recovery as demonstrated on the ocular space.5,10

Our CRYOTEK® cryopreservation process has been shown to preserve the structural integrity of the HC-HA/PTX3 complex significantly better than heat dehydration—delivering the benefit of the natural tissue to the wound.11,12

 

THE CLINICAL AND ECONOMIC CHALLENGES OF DIVERSE WOUND CONDITIONS AND INFECTIONS

Industry experts recognize the increasing burden of non-healing wound infections.

14.5% of Medicare beneficiaries in 2014 (8.2 million patients) were diagnosed with at least one type of wound or wound-related infection. Listed by prevalence:

  1. Surgical wound infections, the largest category, at 4%
  2. Diabetic wound infections 3.4%
  3. Non-healing surgical wounds 3%13

Estimated conservatively, their annual cost is $28 billion. This cost could range from $31.7 billion to $96.8 billion including wounds as a secondary diagnosis.13

NEOX CORD 1K: A treatment option specifically targeted to complex DFU Wagner 3-4 wounds

  • NEOX CORD 1K can help expedite healing in patients with Wagner 3-4 ulcers with an average of 1.5 applications2,3
  •  NEOX CORD 1K is suitable for complex wounds with exposure of muscle, tendon and bone where many conventional advanced skin substitutes and skin grafts are contraindicated2,3
  • Our phase II prospective Biologics License Application (BLA) trial reinforces the clinical outcomes1
  • Our product pipeline is focused on patients most at risk for amputation
  • Our technology can help reduce the cost of care by helping to expedite functional recovery for the patient2,4

NEOX UMBILICAL CORD ALLOGRAFTS (UC) VS. AMNIOTIC MEMBRANE (AM)

Meeting the Challenge of Complex Wound Healing

  • Learn more about how Amniox is harnessing the unique power of human birth tissue through the NEOX family of products by downloading the corporate brochure. Fill out the form below to receive a copy:
  • By clicking the button below, I agree to receive marketing communications from Amniox I am aware that I can unsubscribe at any time.

Valuable Resources

Advanced Therapy Treatments in Lower Extremity Wound Healing

Advanced wound therapy treatments are experiencing a rapid adoption rate as an adjunct to the standard of care. In this webinar, Dr. Alan Block provided a contemporary overview of Amniotic Membrane and Umbilical Cord transplantation and shared challenging cases specific to a variety of lower extremity applications where expedited wound healing and functional recovery are a concern.

You can watch Dr. Block’s webinar in its entirety by signing up for the Physician Portal and accessing archived webinars on-demand by clicking the button below.

  • Request More Information
    Learn more about how our family of products can orchestrate regenerative healing which may improve patient outcomes. Fill out the form below and a representative will contact you.
  • By clicking the button below, I agree to receive marketing communications from Amniox I am aware that I can unsubscribe at any time.Privacy PolicyDo Not Sell My Personal Information

References

1. Marston WA, Lantis II JC, Wu SC, et al. Wound Repair Regen. 2020;1-6.
2. Caputo WJ, Vaquero C, Monterosa A, et al. Wound Repair Regen. 2016;24(5):885-893.
3. Raphael A. J Wound Care. 2016;25(Sup7):S10-17.
4. Bemenderfer TB, Anderson RB, Odum SM, Davis WH. J Foot Ankle Surg. 2019;58(1):97-102.
5. Tseng SC. Invest Ophthalmol Vis Sci. 2016;57(5):ORSFh1-ORSFh8.
6. He H, Li W, Tseng DY, et al. J Biol Chem. 2009;284:20136-46.
7. He H, Zhang S, Tighe S, Son J, Tseng SC. J Biol Chem. 2013;288:25792-803.
8. Zhang S, He H, Day AJ, et al. J Biol Chem. 2012;287:12433-44.
9. Zhang S, Zhu YT, Chen SY, et al. J Biol Chem. 2014;289:13531-42.
10. Tseng SC, Tsubota K. Am J Ophthalmol. 1997 Dec;124(6):825-35.
11. Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.
12. Tan EK, Cooke M, Mandrycky C, et al. J Biomaterial T Eng. 2014;4:379-388.
13. Nussbaum SR, Carter MJ, Fife CE, et al. Value Health. 2018 Jan;21(1):27-32.
14. Raphael A, Gonzales J. J Wound Care. 2017;26(Sup10):S38-44.
15. Kirsner RS, Sabolinski ML, Parsons NB, Skornicki M, Marston WA. Wound Repair Regen. 2015 Sep;23(5):737-44.
16. Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. Int Wound J. 2017 Jun;14(3):569-577.